LeukoStrat CDx FLT3 Mutation Assay

Somatic Gene Mutation Detection System

FDA Premarket Approval P160040 S003

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Approval for a manufacturing site located at invivoscribe technologies, inc. , 10222 barnes canyon rd. , bldg. 1, san diego, california.

DeviceLeukoStrat CDx FLT3 Mutation Assay
Classification NameSomatic Gene Mutation Detection System
Generic NameSomatic Gene Mutation Detection System
ApplicantINVIVOSCRIBE TECHNOLOGIES, INC
Date Received2018-04-12
Decision Date2018-12-07
PMAP160040
SupplementS003
Product CodeOWD
Docket NumberPremarket Approval (PMA) // Quick Links: Skip To Main Page Content Skip To Search Skip To Topics Menu Skip To Common Links U.S. Food & Drug Administration   Follow FDA En Español Search FDA   Home Food Drugs Medical Devices Radia
Advisory CommitteePathology
Supplement TypeNormal 180 Day Track No User Fee
Supplement ReasonLocation Change - Manufacturer/sterilizer/packager/supplier
Expedited ReviewNo
Combination Product No
Applicant Address INVIVOSCRIBE TECHNOLOGIES, INC 6330 Nancy Ridge Drive suite 106 san Diego, CA 92121

Supplemental Filings

Supplement NumberDateSupplement Type
P160040Original Filing
S010 2022-03-15 30-day Notice
S009 2021-07-12 30-day Notice
S008 2021-07-09 Special (immediate Track)
S007
S006 2019-10-17 Normal 180 Day Track
S005
S004 2018-11-06 Real-time Process
S003 2018-04-12 Normal 180 Day Track No User Fee
S002 2018-03-30 Normal 180 Day Track
S001 2017-12-22 30-day Notice

NIH GUDID Devices

Device IDPMASupp
00850052003685 P160040 004
00850052003739 P160040 006
00810022732571 P160040 006

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.